Ad
related to: platinum resistant ovarian cancer treatments
Search results
Results from the WOW.Com Content Network
Mirvetuximab soravtansine is indicated for the treatment of adults with folate receptor alpha (FRα) positive, platinum-resistant epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. [2] [5] [6] Recipients are selected for therapy based on an FDA ...
Sutro Biopharma Announces Selected Dose for Luvelta and Topline Results from Dose-Optimization Portion of REFRαME-O1 Trial in Platinum Resistant Ovarian Cancer - 32% objective response rate (ORR) in evaluable patients at the 5.2 mg/kg starting dose – the selected dose for randomized portion (Part 2) of ongoing registrational REFRαME-O1 trial -
COPENHAGEN, Denmark, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced initial data showing signs of clinical activity in heavily pre-treated patients with platinum-resistant ovarian cancer (PROC) treated with TransCon IL-2 β/γ in combination with chemotherapy in its ongoing Phase 1/2 IL-Believe Trial of ...
If ovarian cancer recurs, it is considered partially platinum-sensitive or platinum-resistant, based on the time since the last recurrence treated with platins: partially platinum-sensitive cancers recurred 6–12 months after last treatment, and platinum-resistant cancers have an interval of less than 6 months.
As PTX-200, triciribine is currently in a Phase Ib/II study in breast cancer [13]) and a Phase Ib trial in platinum resistant ovarian cancer. [14] These trials completed in 2020 and 2019 respectively without publishing data, suggesting negative results.
[25] it started in 2013 a phase III for metastatic germline BRCA mutated breast cancer. [26] Veliparib June 2014 in phase III trials, for advanced ovarian cancer, triple-negative breast cancer and in non-small cell lung cancer (NSCLC). [27] Pamiparib (BGB-290) For ovarian cancer, 1st patient enrolled May 2018. [28] It is a PARP1 and PARP2 ...
Key efficacy outcomes in 24 evaluable Platinum-Resistant Ovarian Cancer patients show: Overall response rate was 37.5% (confirmed ORR in 4 out of 9 patients). Clinical benefit was observed in 79% ...
This companion imaging agent identifies cells expressing the folate receptor, including cancer and inflammatory cells. [ 2 ] Etarfolatide is currently being investigated together with the corresponding small molecule drug conjugate (SMDC) vintafolide in a Phase 3 study in platinum-resistant ovarian cancer and in a Phase 2b study in non-small ...
Ad
related to: platinum resistant ovarian cancer treatments